TD Cowen lowered the firm’s price target on BioCryst to $20 from $25 and keeps an Outperform rating on the shares. The firm said its R&D day highlighted promising new programs in rare diseases. While management understandably is investing in the pipeline using the same approach that led to Orladeyo success Cowen also understands investor frustration given Orladeyo s compelling standalone value.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BCRX:
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®
- BioCryst announces drug discovery updates ahead of R&D day
- BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months
- Clearside to receive $5M upfront in license agreement with BioCryst
